Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

$2.5m Contract Award for development of clinical self-test

York, U.K. 12 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has been awarded a significant contract with an expected value of approximately US$2.5 million to provide project management and expert technical support for the development and regulatory submission of a clinical self-test.

The Company has signed a Services Agreement with this UK-based customer to be delivered in phases over an 18-month period via orders under the Services Agreement. The project represents a strategically important contract in the clinical self-test diagnostics sector and demonstrates Abingdon Health's expertise in managing complex, multi-stakeholder international diagnostic programmes. The contract will commence shortly with the majority of the revenues to be recognised in the financial year ending 30 June 2027.

Abingdon Health will provide end-to-end project management and technical support across three key phases: Feasibility, Design & Development and Verification & Validation. The work leverages the Company's established capabilities in lateral flow test development, clinical diagnostics, ISO 13485:2016 quality management systems, and regulatory pathways.

This contract award underscores Abingdon Health's position as a leading provider of integrated CDMO/CRO services for rapid diagnostic tests.

Dr Chris Hand, Executive Chairman, commented: "We are delighted to have been selected and to be working with this client on this important global health project. Our multidisciplinary in-house immunodiagnostics specialists, regulatory experts, and programme managers are ideally suited to deliver this complex international programme. This award reinforces our strategic position in the point-of-contact diagnostics market and demonstrates the value of our CDMO/CRO platform to major international organisations."

Enquiries:

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.